Merck Press Releases

Published on September 11, 2013 - 08:50 GMT

Merck and AstraZeneca Enter License Agreement for Investigational Oral WEE1 Kinase Inhibitor Therapy for Cancer

WHITEHOUSE STATION, N.J. LONDON--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and AstraZeneca (NYSE: AZN) today announced a worldwide licensing agreement for Merck’s oral small molecule inhibitor of WEE1 kinase (MK …

Distribution channels: Companies

Published on September 11, 2013 - 08:46 GMT

Merck and AstraZeneca Enter License Agreement for Investigational Oral WEE1 Kinase Inhibitor Therapy for Cancer

WHITEHOUSE STATION, N.J. LONDON--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and AstraZeneca (NYSE: AZN) today announced a worldwide licensing agreement for Merck’s oral small molecule inhibitor of WEE1 kinase (MK …

Distribution channels: Companies

Published on September 10, 2013 - 12:21 GMT

Merck to Present at the Morgan Stanley Global Healthcare Conference

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Roger M. Perlmutter, executive vice president and president, Merck Research Laboratories, is scheduled to present at the …

Distribution channels: Companies

Published on September 9, 2013 - 14:04 GMT

Merck Announces FDA Acceptance of New Drug Application for Investigational Fertility Treatment

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the New Drug Application (NDA) for its investigational fertility treatment, corifollitropin alfa, has been accepted for …

Distribution channels: Companies

Published on September 9, 2013 - 14:00 GMT

Merck and Israel’s Maccabi Healthcare to Leverage Unique Real-World Database to Inform Novel Health Approaches

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Maccabi Healthcare Services, a two million-member health care provider in Israel, are starting a new, multi-year agreement to leverage real-world data from Maccabi’s unique …

Distribution channels: Companies

Published on September 9, 2013 - 14:00 GMT

Merck Announces FDA Acceptance of New Drug Application for Investigational Fertility Treatment

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the New Drug Application (NDA) for its investigational fertility treatment, corifollitropin alfa, has been accepted for …

Distribution channels: Companies

Published on September 4, 2013 - 22:16 GMT

Merck’s Durham Site Receives U.S. FDA Licensure for Varicella Bulk

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to manufacture bulk varicella at the company’s site in Durham, N.C., for use in Merck’s …

Distribution channels: Companies

Published on August 1, 2013 - 16:52 GMT

Merck and Her Campus Ask College-Aged Women to Take the Pledge to Plan It Forward For Their Futures by Evaluating How Today’s ...

On- or off-campus housing? Which major to declare? An internship or work study? These are questions often debated by college-aged women at the start of a new school year. One question that they may not be asking themselves is, “how will the decisions I …

Distribution channels: Companies

Published on July 31, 2013 - 13:13 GMT

Merck Publishes 2012 Global Corporate Responsibility Report

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today issued its 2012 global corporate responsibility report. The report, available at www.merckresponsibility.com, focuses on Merck's corporate responsibility activities, …

Distribution channels: Companies

Published on July 30, 2013 - 11:39 GMT

Merck Announces Second-Quarter 2013 Financial Results

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2013. $ in millions, except EPS amounts Second Quarter 2013 Second Quarter …

Distribution channels: Companies

Published on July 29, 2013 - 22:37 GMT

Merck Reaffirms Commitment to State AIDS Drug Assistance Programs (ADAPs) Through 2014

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the ADAP Crisis Task Force (ACTF) today announced that the company will extend its commitment to support state AIDS Drug Assistance Programs (ADAPs), which have struggled to meet …

Distribution channels: Companies

Published on July 29, 2013 - 21:10 GMT

Merck Applauds Colombia for First PAHO/WHO Verification of Elimination of River Blindness

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, applauds the government of Colombia whose work with the MECTIZAN® Donation Program and The Carter Center-sponsored Onchocerciasis Elimination …

Distribution channels: Companies

Published on July 26, 2013 - 13:31 GMT

Merck Statement Regarding CHMP Review of Incretin-Based Therapies for Type 2 Diabetes, Including Sitagliptin

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, issued the following statement regarding the conclusion of the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) …

Distribution channels: Companies

Published on July 26, 2013 - 13:27 GMT

Merck Statement Regarding CHMP Review of Incretin-Based Therapies for Type 2 Diabetes, Including Sitagliptin

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, issued the following statement regarding the conclusion of the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) …

Distribution channels: Companies

Published on July 24, 2013 - 20:46 GMT

Merck Announces Fourth-Quarter 2013 Dividend

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.43 per share on the company’s common stock for the fourth quarter of …

Distribution channels: Companies

Published on July 24, 2013 - 12:33 GMT

Merck Announces FDA Acceptance of New Drug Application for Vorapaxar, Investigational Anti-Thrombotic Medicine

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the New Drug Application (NDA) for its investigational anti-thrombotic medicine, vorapaxar, has been accepted for standard …

Distribution channels: Companies

Published on July 24, 2013 - 12:32 GMT

Merck Announces FDA Acceptance of New Drug Application for Vorapaxar, Investigational Anti-Thrombotic Medicine

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the New Drug Application (NDA) for its investigational anti-thrombotic medicine, vorapaxar, has been accepted for standard …

Distribution channels: Companies

Published on July 16, 2013 - 17:12 GMT

Merck Statement on FDA Advisory Committee Meeting About Sugammadex Sodium Injection

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, confirmed today that the U.S. Food and Drug Administration (FDA) has cancelled Thursday’s discussion of sugammadex at the Anesthetic and …

Distribution channels: Companies

Published on July 16, 2013 - 17:07 GMT

Merck Statement on FDA Advisory Committee Meeting About Sugammadex Sodium Injection

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, confirmed today that the U.S. Food and Drug Administration (FDA) has cancelled Thursday’s discussion of sugammadex at the Anesthetic and …

Distribution channels: Companies

Published on July 14, 2013 - 12:39 GMT

Merck Presents Findings from Phase 1b Study of Investigational BACE Inhibitor, MK-8931, in Patients with Alzheimer’s Disease

Merck, known as MSD outside the United States and Canada, today announced the presentation of results from a Phase Ib study showing a dose-dependent decrease in β amyloid levels in cerebral spinal fluid (CSF) following administration of MK-8931, Merck’s …

Distribution channels: Companies

Merck Press Releases Distributed by EIN Presswire